Because ALCAM has been implicated in the aggressiveness of breast cancer [68,69], colorectal cancer [70,71], lung cancer [72], melanoma [73,74], and glioblastoma [75], the ALCAM/syntenin interaction might regulate cell motility through controlling adhesion strength. Here, SDCBP is linked to breast cancer.